Biogen Idec, Inc. (Massachusetts) First Quarter 2014 Revenues Reach $2.1 Billion Driven By Continued Strength Of MS Franchise

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Biogen Idec Inc. (NASDAQ: BIIB) today reported first quarter 2014 results, including revenue of $2.1 billion, a 51% increase compared to the first quarter of 2013. The revenue growth year-over-year was driven by strong TECFIDERA performance and from recording 100% of TYSABRI® revenues following our acquisition of complete rights for the asset in the second quarter of 2013. First quarter 2014 non-GAAP diluted earnings per share (EPS) were $2.47, an increase of 25% over the first quarter of 2013. Non-GAAP net income attributable to Biogen Idec for the year was $587 million, an increase of 25% over the first quarter of 2013.

Help employers find you! Check out all the jobs and post your resume.

Back to news